203 related articles for article (PubMed ID: 22655027)
1. Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage.
Merolla F; Luise C; Muller MT; Pacelli R; Fusco A; Celetti A
PLoS One; 2012; 7(5):e36177. PubMed ID: 22655027
[TBL] [Abstract][Full Text] [Related]
2. Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.
Luise C; Merolla F; Leone V; Paladino S; Sarnataro D; Fusco A; Celetti A
PLoS One; 2012; 7(11):e49298. PubMed ID: 23145146
[TBL] [Abstract][Full Text] [Related]
3. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.
Laxmi A; Gupta P; Gupta J
Cancer Biomark; 2019; 24(4):383-393. PubMed ID: 30909182
[TBL] [Abstract][Full Text] [Related]
4. Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control.
Thanasopoulou A; Stravopodis DJ; Dimas KS; Schwaller J; Anastasiadou E
PLoS One; 2012; 7(2):e31007. PubMed ID: 22363533
[TBL] [Abstract][Full Text] [Related]
5. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
6. Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors.
Staibano S; Ilardi G; Leone V; Luise C; Merolla F; Esposito F; Morra F; Siano M; Franco R; Fusco A; Chieffi P; Celetti A
BMC Cancer; 2013 Sep; 13():433. PubMed ID: 24059746
[TBL] [Abstract][Full Text] [Related]
7. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Suzuki M; Makinoshima H; Matsumoto S; Suzuki A; Mimaki S; Matsushima K; Yoh K; Goto K; Suzuki Y; Ishii G; Ochiai A; Tsuta K; Shibata T; Kohno T; Esumi H; Tsuchihara K
Cancer Sci; 2013 Jul; 104(7):896-903. PubMed ID: 23578175
[TBL] [Abstract][Full Text] [Related]
8. CCDC6: the identity of a protein known to be partner in fusion.
Cerrato A; Merolla F; Morra F; Celetti A
Int J Cancer; 2018 Apr; 142(7):1300-1308. PubMed ID: 29044514
[TBL] [Abstract][Full Text] [Related]
9. FBXW7-mediated degradation of CCDC6 is impaired by ATM during DNA damage response in lung cancer cells.
Zhao J; Tang J; Men W; Ren K
FEBS Lett; 2012 Dec; 586(24):4257-63. PubMed ID: 23108047
[TBL] [Abstract][Full Text] [Related]
10. Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A
Oncotarget; 2015 Jun; 6(17):15628-38. PubMed ID: 25970781
[TBL] [Abstract][Full Text] [Related]
11. FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
Morra F; Luise C; Merolla F; Poser I; Visconti R; Ilardi G; Paladino S; Inuzuka H; Guggino G; Monaco R; Colecchia D; Monaco G; Cerrato A; Chiariello M; Denning K; Claudio PP; Staibano S; Celetti A
Oncotarget; 2015 May; 6(14):12697-709. PubMed ID: 25885523
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Polo-like kinase 1 by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase 2A.
Jang YJ; Ji JH; Choi YC; Ryu CJ; Ko SY
J Biol Chem; 2007 Jan; 282(4):2473-82. PubMed ID: 17121863
[TBL] [Abstract][Full Text] [Related]
13. PP4 is a gamma H2AX phosphatase required for recovery from the DNA damage checkpoint.
Nakada S; Chen GI; Gingras AC; Durocher D
EMBO Rep; 2008 Oct; 9(10):1019-26. PubMed ID: 18758438
[TBL] [Abstract][Full Text] [Related]
14. Protein phosphatase 6 interacts with the DNA-dependent protein kinase catalytic subunit and dephosphorylates gamma-H2AX.
Douglas P; Zhong J; Ye R; Moorhead GB; Xu X; Lees-Miller SP
Mol Cell Biol; 2010 Mar; 30(6):1368-81. PubMed ID: 20065038
[TBL] [Abstract][Full Text] [Related]
15. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
[TBL] [Abstract][Full Text] [Related]
16. CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1.
Leone V; Mansueto G; Pierantoni GM; Tornincasa M; Merolla F; Cerrato A; Santoro M; Grieco M; Scaloni A; Celetti A; Fusco A
Oncogene; 2010 Jul; 29(30):4341-51. PubMed ID: 20498639
[TBL] [Abstract][Full Text] [Related]
17. Silencing of CCDC6 reduces the expression of 14-3-3σ in colorectal carcinoma cells.
Thanasopoulou A; Xanthopoulou AG; Anagnostopoulos AK; Konstantakou EG; Margaritis LH; Papassideri IS; Stravopodis DJ; Tsangaris GT; Anastasiadou E
Anticancer Res; 2012 Mar; 32(3):907-13. PubMed ID: 22399611
[TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomic analysis reveals that PP4 dephosphorylates KAP-1 impacting the DNA damage response.
Lee DH; Goodarzi AA; Adelmant GO; Pan Y; Jeggo PA; Marto JA; Chowdhury D
EMBO J; 2012 May; 31(10):2403-15. PubMed ID: 22491012
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase 4 catalytic subunit regulates Cdk1 activity and microtubule organization via NDEL1 dephosphorylation.
Toyo-oka K; Mori D; Yano Y; Shiota M; Iwao H; Goto H; Inagaki M; Hiraiwa N; Muramatsu M; Wynshaw-Boris A; Yoshiki A; Hirotsune S
J Cell Biol; 2008 Mar; 180(6):1133-47. PubMed ID: 18347064
[TBL] [Abstract][Full Text] [Related]
20. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Lee HJ; Hwang HI; Jang YJ
Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
